Literature DB >> 30174925

Squamous cell carcinoma transformation from adenocarcinoma as an acquired resistance after the EGFR TKI therapy in (EGFR-mutated) non-small cell lung cancer.

Shinji Shinohara1, Yoshinobu Ichiki1, Yukiko Fukuichi1, Yohei Honda1, Masatoshi Kanayama1, Akihiro Taira1, Yusuke Nabe1, Taiji Kuwata1, Masaru Takenaka1, Soichi Oka1, Yasuhiro Chikaishi1, Ayako Hirai1, Naoko Imanishi1, Koji Kuroda1, Kazue Yoneda1, Hirotsugu Noguchi2, Fumihiro Tanaka1.   

Abstract

Entities:  

Year:  2018        PMID： 30174925      PMCID： PMC6105982          DOI： 10.21037/jtd.2018.06.83

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  8 in total

1.  Squamous Cell Carcinoma "Transformation" Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas.

Authors:  Agita Jukna; Gloria Montanari; Maria Cecilia Mengoli; Alberto Cavazza; Marisa Covi; Fausto Barbieri; Federica Bertolini; Giulio Rossi
Journal:  J Thorac Oncol       Date:  2015-12-30       Impact factor: 15.609

2.  Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition.

Authors:  Pavel A Levin; Melissa Mayer; Sharon Hoskin; Joseph Sailors; Dwight H Oliver; David E Gerber
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

3.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authors:  Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956

4.  Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.

Authors:  Lucia Longo; Maria Cecilia Mengoli; Federica Bertolini; Stefania Bettelli; Samantha Manfredini; Giulio Rossi
Journal:  Lung Cancer       Date:  2016-11-17       Impact factor: 5.705

Review 5.  Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors.

Authors:  Rita Dorantes-Heredia; José Manuel Ruiz-Morales; Fernando Cano-García
Journal:  Transl Lung Cancer Res       Date:  2016-08

Review 6.  Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

Authors:  Kim-Son H Nguyen; Susumu Kobayashi; Daniel B Costa
Journal:  Clin Lung Cancer       Date:  2009-07       Impact factor: 4.785

7.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

8.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

Authors:  Geoffrey R Oxnard; Kenneth S Thress; Ryan S Alden; Rachael Lawrance; Cloud P Paweletz; Mireille Cantarini; James Chih-Hsin Yang; J Carl Barrett; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544
  8 in total
  9 in total

1.  Histologic Changes in Non-Small Cell Lung Cancer under Various Treatments: A Comparison of Histology and Mutation Status in Serial Samples.

Authors:  Chang Gok Woo; Seung-Myoung Son; Ho-Chang Lee; Hye Sook Han; Ki Hyeong Lee; Dohun Kim; Eung-Gook Kim; Ok-Jun Lee
Journal:  Cancer Res Treat       Date:  2021-09-24       Impact factor: 5.036

2.  Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.

Authors:  Adam J Schoenfeld; Joseph M Chan; Daisuke Kubota; Hiroki Sato; Hira Rizvi; Yahya Daneshbod; Jason C Chang; Paul K Paik; Michael Offin; Maria E Arcila; Monika A Davare; Ujwal Shinde; Dana Pe'er; Natasha Rekhtman; Mark G Kris; Romel Somwar; Gregory J Riely; Marc Ladanyi; Helena A Yu
Journal:  Clin Cancer Res       Date:  2020-01-07       Impact factor: 12.531

Review 3.  Pathological transition as the arising mechanism for drug resistance in lung cancer.

Authors:  Yueqing Chen; Waiying Yvonne Tang; Xinyuan Tong; Hongbin Ji
Journal:  Cancer Commun (Lond)       Date:  2019-10-01

4.  Characterization of non-small cell lung cancer transforming to small cell lung cancer and its response to EGFR-TKI: a case report.

Authors:  Guotao Fang; Weiwei Liu; Yanhong Shang; Ran Huo; Xiaoliang Shi; Yanan Wang; Jinghua Li
Journal:  Ann Transl Med       Date:  2022-01

Review 5.  Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.

Authors:  Fiorella Calabrese; Federica Pezzuto; Francesca Lunardi; Francesco Fortarezza; Sofia-Eleni Tzorakoleftheraki; Maria Vittoria Resi; Mariaenrica Tiné; Giulia Pasello; Paul Hofman
Journal:  Int J Mol Sci       Date:  2022-04-09       Impact factor: 6.208

Review 6.  T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review.

Authors:  Yusaku Kusaba; Yuichiro Takeda; Sakurako Abe; Akinari Tsukada; Go Naka
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

Review 7.  Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC.

Authors:  Jennifer Novak; Ravi Salgia; Howard West; Miguel A Villalona-Calero; Sagus Sampath; Terence Williams; Victoria Villaflor; Erminia Massarelli; Ranjan Pathak; Marianna Koczywas; Brittney Chau; Arya Amini
Journal:  Cancers (Basel)       Date:  2022-08-18       Impact factor: 6.575

8.  Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.

Authors:  Svenja Wagener-Ryczek; Carina Heydt; Juliane Süptitz; Sebastian Michels; Markus Falk; Christina Alidousty; Jana Fassunke; Michaela Angelika Ihle; Markus Tiemann; Lukas Heukamp; Jürgen Wolf; Reinhard Büttner; Sabine Merkelbach-Bruse
Journal:  BMC Cancer       Date:  2020-05-12       Impact factor: 4.430

Review 9.  [Mechanism of Histologic Transformation of Drive Gene Positive Lung Adenocarcinoma in Targeted Therapy and Treatment Strategy].

Authors:  Tongji Xie; Yan Li; Puyuan Xing
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-08-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.